{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T06:27:49Z","timestamp":1794378469132,"version":"4.9.0"},"reference-count":184,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biotechnology Advances"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.biotechadv.2026.108862","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T07:45:22Z","timestamp":1772610322000},"page":"108862","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["RNA therapeutics 2.0: Expanding the landscape from mRNA vaccines to splicing modulators and beyond"],"prefix":"10.1016","volume":"89","author":[{"given":"Pawan N.","family":"Karwa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil S.","family":"Sakle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biotechadv.2026.108862_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/nat.2016.0657","article-title":"FDA approves eteplirsen for Duchenne muscular dystrophy: the next chapter in the eteplirsen saga","volume":"27","author":"Aartsma-Rus","year":"2017","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0010","first-page":"1223","article-title":"A cytidine deaminase\u2013Cas13 fusion expands RNA base editing capabilities","volume":"37","author":"Abudayyeh","year":"2019","journal-title":"Nat. Biotechnol."},{"issue":"7","key":"10.1016\/j.biotechadv.2026.108862_bb0015","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.3390\/pharmaceutics15071972","article-title":"Recent advancement in mRNA vaccine development and applications","volume":"15","author":"Al Fayez","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biotechadv.2026.108862_bb0020","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3390\/ph16020291","article-title":"Analytical techniques for the characterization and quantification of monoclonal antibodies","volume":"16","author":"Alhazmi","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.biotechadv.2026.108862_bb0025","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nbt.1807","article-title":"Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes","volume":"29","author":"Alvarez-Erviti","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0030","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/jcph.2337","article-title":"Pharmacokinetics and pharmacodynamics of GalNAc-conjugated siRNAs","volume":"64","author":"An","year":"2024","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0035","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.omtn.2019.02.018","article-title":"A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA","volume":"15","author":"Baiersd\u00f6rfer","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"1","key":"10.1016\/j.biotechadv.2026.108862_bb0040","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3390\/cells9010137","article-title":"RNA-based therapeutics: from antisense oligonucleotides to miRNAs","volume":"9","author":"Bajan","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.biotechadv.2026.108862_bb0045","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1056\/NEJMoa2009965","article-title":"Risdiplam in type 1 spinal muscular atrophy","volume":"384","author":"Baranello","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0050","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0040-4020(01)88752-4","article-title":"Advances in the synthesis of oligonucleotides by the phosphoramidite approach","volume":"48","author":"Beaucage","year":"1992","journal-title":"Tetrahedron"},{"key":"10.1016\/j.biotechadv.2026.108862_bb0055","article-title":"J06 pivot-HD: a phase 2, randomised, placebo-controlled study to evaluate the safety and efficacy of PTC518 in subjects with Huntington\u2019s disease","volume":"93","author":"Beers","year":"2022","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.biotechadv.2026.108862_bb0060","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev-med-041217-010829","article-title":"Therapeutic antisense oligonucleotides are coming of age","volume":"70","author":"Bennett","year":"2019","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0065","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1146\/annurev-neuro-070918-050501","article-title":"Antisense oligonucleotide therapies for neurodegenerative diseases","volume":"42","author":"Bennett","year":"2019","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0070","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1146\/annurev-pharmtox-010919-023738","article-title":"Antisense drugs make sense for neurological diseases","volume":"61","author":"Bennett","year":"2021","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0075","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/bph.17302","article-title":"Mitigating off-target effects of small RNAs: conventional approaches, network theory and artificial intelligence","volume":"182","author":"Bereczki","year":"2025","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0080","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jconrel.2019.04.043","article-title":"Effects of cationic adjuvant formulation particle type, fluidity and immunomodulators on delivery and immunogenicity of saRNA","volume":"304","author":"Blakney","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biotechadv.2026.108862_bb0085","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3390\/vaccines9020097","article-title":"An update on self-amplifying mRNA vaccine development","volume":"9","author":"Blakney","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.biotechadv.2026.108862_bb0090","article-title":"Self-amplifying RNA in pandemic preparedness","volume":"12","author":"Blakney","year":"2021","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.biotechadv.2026.108862_bb0095","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41434-020-00204-y","article-title":"Self-amplifying RNA vaccines for infectious diseases","volume":"28","author":"Bloom","year":"2021","journal-title":"Gene Ther."},{"issue":"9","key":"10.1016\/j.biotechadv.2026.108862_bb0100","first-page":"2780","article-title":"Development of saRNA vaccines against Zika virus","volume":"29","author":"Bloom","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0105","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.3390\/genes14071378","article-title":"Therapeutic targeting of RNA splicing in cancer","volume":"14","author":"Bonner","year":"2023","journal-title":"Genes (Basel)"},{"issue":"6","key":"10.1016\/j.biotechadv.2026.108862_bb0110","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.ymthe.2023.01.005","article-title":"RNA editing: expanding the potential of RNA therapeutics","volume":"31","author":"Booth","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0115","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1586\/14737175.2015.1028369","article-title":"Focused ultrasound-mediated drug delivery through the blood\u2013brain barrier","volume":"15","author":"Burgess","year":"2015","journal-title":"Expert. Rev. Neurother."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0120","doi-asserted-by":"crossref","first-page":"5976","DOI":"10.1172\/JCI134915","article-title":"mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer","volume":"130","author":"Cafri","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0125","doi-asserted-by":"crossref","first-page":"4809","DOI":"10.3390\/ijms25094809","article-title":"Antisense oligonucleotides (ASOs) in motor neuron diseases: a road to cure in light and shade","volume":"25","author":"Cantara","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.biotechadv.2026.108862_bb0130","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1016\/j.ymthe.2025.03.060","article-title":"The advent of clinical self-amplifying RNA vaccines","volume":"33","author":"Casmil","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cell.2025.11.023","article-title":"Distinct components of mRNA vaccines cooperate to promote T follicular helper cell responses","volume":"188","author":"Casta\u00f1o","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.biotechadv.2026.108862_bb0140","doi-asserted-by":"crossref","DOI":"10.1038\/s41565-025-01975-4","article-title":"Designing lipid nanoparticles using a transformer-based neural network","author":"Chan","year":"2025","journal-title":"Nat. Nanotechnol."},{"issue":"2","key":"10.1016\/j.biotechadv.2026.108862_bb0145","doi-asserted-by":"crossref","first-page":"588","DOI":"10.7150\/thno.29678","article-title":"Circular RNAs in immune responses and immune diseases","volume":"9","author":"Chen","year":"2019","journal-title":"Theranostics"},{"issue":"7","key":"10.1016\/j.biotechadv.2026.108862_bb0150","doi-asserted-by":"crossref","first-page":"35","DOI":"10.14304\/SURYA.JPR.V4N7.5","article-title":"RNA therapeutics: RNAi and antisense mechanisms and clinical applications","volume":"4","author":"Chery","year":"2016","journal-title":"Postdoc J."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0155","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1001\/jamaneurol.2020.1264","article-title":"Safety, tolerability, and efficacy of viltolarsen in Duchenne muscular dystrophy","volume":"77","author":"Clemens","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0160","series-title":"NCT04740476: An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome","author":"ClinicalTrials.gov","year":"2025"},{"key":"10.1016\/j.biotechadv.2026.108862_bb0165","series-title":"Branaplam in Huntington\u2019s Disease","author":"ClinicalTrials.gov","year":"2025"},{"key":"10.1016\/j.biotechadv.2026.108862_bb0170","series-title":"PTC-518 in Huntington\u2019s Disease","author":"ClinicalTrials.gov","year":"2025"},{"key":"10.1016\/j.biotechadv.2026.108862_bb0175","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1126\/science.aaq0180","article-title":"RNA editing with CRISPR-Cas13","volume":"358","author":"Cox","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.biotechadv.2026.108862_bb0180","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cmet.2018.03.004","article-title":"RNA-targeted therapeutics","volume":"27","author":"Crooke","year":"2018","journal-title":"Cell Metab."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0185","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkaf788","article-title":"Internal ribosome entry sites enhance translation in trans in antisense non-coding SINEUP and circular RNAs","volume":"53","author":"D\u2019Agostino","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0190","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2021.628137","article-title":"The limitless future of RNA therapeutics","volume":"9","author":"Damase","year":"2021","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0195","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.cpt.2024.11.003","article-title":"Circular RNA vaccines: pioneering the next-gen cancer immunotherapy","volume":"3","author":"Das","year":"2024","journal-title":"Cancer Pathog. Ther."},{"issue":"8","key":"10.1016\/j.biotechadv.2026.108862_bb0200","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.ymthe.2020.06.015","article-title":"Delivery of oligonucleotides to the liver with GalNAc: from research to registered therapeutic drug","volume":"28","author":"Debacker","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0205","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1124\/jpet.107.131318","article-title":"Identification and design of peptides as a new drug delivery system for the brain","volume":"324","author":"Demeule","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0210","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.biopha.2018.09.097","article-title":"Cell-penetrating peptides: a concise review with emphasis on biomedical applications","volume":"108","author":"Derakhshankhah","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0215","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1007\/s40265-020-01410-z","article-title":"Risdiplam: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.biotechadv.2026.108862_bb0220","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s40164-025-00648-1","article-title":"RNA modifications in the tumor microenvironment: insights into the cancer\u2013immunity cycle and beyond","volume":"14","author":"Ding","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0225","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/d41586-021-02483-w","article-title":"The tangled history of mRNA vaccines","volume":"597","author":"Dolgin","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.biotechadv.2026.108862_bb0230","doi-asserted-by":"crossref","first-page":"R163","DOI":"10.1093\/hmg\/ddy171","article-title":"Exon-skipping advances for Duchenne muscular dystrophy","volume":"27","author":"Echevarr\u00eda","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0235","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1089\/nat.2014.0506","article-title":"Phosphorothioates, essential components of therapeutic oligonucleotides","volume":"24","author":"Eckstein","year":"2014","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0240","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.molmed.2021.04.005","article-title":"Therapeutic modulation of RNA splicing in malignant and non-malignant disease","volume":"27","author":"El Marabti","year":"2021","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0245","first-page":"1","article-title":"Self-amplifying RNA vaccine technology","volume":"44","author":"Erasmus","year":"2020","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0250","doi-asserted-by":"crossref","first-page":"572","DOI":"10.4062\/biomolther.2025.022","article-title":"RNA therapeutics: focus on antisense oligonucleotides in the nervous system","volume":"33","author":"Ertural","year":"2025","journal-title":"Biomol. Ther. (Seoul)"},{"key":"10.1016\/j.biotechadv.2026.108862_bb0255","series-title":"Guideline on Quality, Non-Clinical and Clinical Aspects of Gene Therapy Medicinal Products","author":"European Medicines Agency","year":"2018"},{"key":"10.1016\/j.biotechadv.2026.108862_bb0260","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.710738","article-title":"RNA therapeutics \u2013 research and clinical advancements","volume":"8","author":"Feng","year":"2021","journal-title":"Front. Mol. Biosci."},{"issue":"7","key":"10.1016\/j.biotechadv.2026.108862_bb0265","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.3390\/vaccines11071172","article-title":"Nanoparticle-based adjuvants and delivery systems for modern vaccines","volume":"11","author":"Filipi\u0107","year":"2023","journal-title":"Vaccines"},{"key":"10.1016\/j.biotechadv.2026.108862_bb0270","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0275","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.791416","article-title":"Single stranded fully modified-phosphorothioate oligonucleotides can induce structured nuclear inclusions, alter nuclear protein localization and disturb the transcriptome in vitro","volume":"13","author":"Flynn","year":"2022","journal-title":"Front. Genet."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0280","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1136\/gutjnl-2023-331742","article-title":"RNA-based therapies in liver metabolic diseases","volume":"74","author":"Fontanellas","year":"2025","journal-title":"Gut"},{"key":"10.1016\/j.biotechadv.2026.108862_bb0285","first-page":"782","article-title":"Golodirsen induces exon skipping and dystrophin production in Duchenne muscular dystrophy","volume":"87","author":"Frank","year":"2020","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0290","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","article-title":"Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides","volume":"87","author":"Geary","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0295","series-title":"Generative Intelligence in Healthcare","first-page":"310","article-title":"Recent applications of artificial intelligence in the process of drug discovery and development","author":"Goyal","year":"2025"},{"issue":"27","key":"10.1016\/j.biotechadv.2026.108862_bb0300","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1056\/NEJMoa042760","article-title":"Pegaptanib for neovascular age-related macular degeneration","volume":"351","author":"Gragoudas","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0305","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2017.00038","article-title":"Circular RNAs: biogenesis, function and role in human diseases","volume":"4","author":"Greene","year":"2017","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0310","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41580-021-00407-0","article-title":"A guide to machine learning for biologists","volume":"23","author":"Greener","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0315","first-page":"1347","article-title":"Transcriptome-wide off-target RNA editing by CRISPR-Cas13b\u2013ADAR fusions","volume":"37","author":"Gr\u00fcnewald","year":"2019","journal-title":"Nat. Biotechnol."},{"issue":"14","key":"10.1016\/j.biotechadv.2026.108862_bb0320","doi-asserted-by":"crossref","first-page":"6549","DOI":"10.1093\/nar\/gkw533","article-title":"Splice-switching antisense oligonucleotides as therapeutic drugs","volume":"44","author":"Havens","year":"2016","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.biotechadv.2026.108862_bb0325","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s12943-021-01417-4","article-title":"Circular RNAs' cap-independent translation protein and its roles in carcinomas","volume":"20","author":"He","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.biotechadv.2026.108862_bb0330","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1056\/NEJMra1706910","article-title":"Gene therapy","volume":"381","author":"High","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0335","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1158\/0008-5472.CAN-10-4455","article-title":"Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis","volume":"71","author":"Hood","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0340","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0345","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nri.2017.131","article-title":"Towards personalized, tumour-specific, therapeutic vaccines for cancer","volume":"18","author":"Hu","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117753","article-title":"Advancing the next generation of cancer treatment with circular RNAs in CAR-T cell therapy","volume":"181","author":"Huang","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0355","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1016\/j.apsb.2025.03.033","article-title":"Inhaled non-viral delivery systems for RNA therapeutics","volume":"15","author":"Huang","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.biotechadv.2026.108862_bb0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2025.145088","article-title":"Circular RNAs as a therapeutic modality for viral infections and innovative strategies to overcome key challenges: a review","author":"Hussen","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0365","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1007\/s13311-021-01095-6","article-title":"Dravet syndrome: novel approaches for the most common genetic epilepsy","volume":"18","author":"Isom","year":"2021","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.biotechadv.2026.108862_bb0370","first-page":"1","article-title":"Polymer-based RNA delivery","volume":"169","author":"John","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.biotechadv.2026.108862_bb0375","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41525-023-00387-4","article-title":"Breaking the mold with RNA\u2014a \u201cRNAissance\u201d of life science","volume":"9","author":"Jones","year":"2024","journal-title":"npj Genomic Med."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0380","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.biotechadv.2026.108862_bb0385","doi-asserted-by":"crossref","first-page":"eaau6977","DOI":"10.1126\/science.aau6977","article-title":"The biology, function, and biomedical applications of exosomes","volume":"367","author":"Kalluri","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.biotechadv.2026.108862_bb0390","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/nature22341","article-title":"Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer","volume":"546","author":"Kamerkar","year":"2017","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.biotechadv.2026.108862_bb0395","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA immunogenicity by nucleoside modifications","volume":"23","author":"Karik\u00f3","year":"2005","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.biotechadv.2026.108862_bb0400","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/MS9.0000000000002761","article-title":"Circular RNAs: history, metabolism, mechanisms of function, and regulatory roles at a glance","volume":"87","author":"Karimi","year":"2025","journal-title":"Ann. Med. Surg. (Lond.)"},{"key":"10.1016\/j.biotechadv.2026.108862_bb0405","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jconrel.2015.12.032","article-title":"Materials for non-viral intracellular delivery of messenger RNA therapeutics","volume":"240","author":"Kauffman","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biotechadv.2026.108862_bb0410","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1007\/s13346-023-01361-4","article-title":"Innate immune regulations and various siRNA modalities","volume":"13","author":"Kaushal","year":"2023","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0415","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.3390\/cells11172665","article-title":"Applications of CRISPR\/Cas13-based RNA editing in plants","volume":"11","author":"Kavuri","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.biotechadv.2026.108862_bb0420","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.643681","article-title":"Nucleic acid-based therapeutics in orphan neurological disorders: recent developments","volume":"8","author":"Khorkova","year":"2021","journal-title":"Front. Mol. Biosci."},{"issue":"7","key":"10.1016\/j.biotechadv.2026.108862_bb0425","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41573-023-00704-7","article-title":"Amplifying gene expression with RNA-targeted therapeutics","volume":"22","author":"Khorkova","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0430","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nbt.3765","article-title":"The chemical evolution of oligonucleotide therapies of clinical utility","volume":"35","author":"Khvorova","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0435","article-title":"Deep learning approaches for lncRNA-mediated mechanisms: a comprehensive review of recent developments","volume":"24","author":"Kim","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0440","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1056\/NEJMoa1813279","article-title":"Patient-customized oligonucleotide therapy for a rare genetic disease","volume":"381","author":"Kim","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.biotechadv.2026.108862_bb0445","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nrd3625","article-title":"RNA therapeutics: beyond RNA interference and antisense oligonucleotides","volume":"11","author":"Kole","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0450","series-title":"Korro Announces Selection of its First Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)","author":"Korro Bio","year":"2023"},{"key":"10.1016\/j.biotechadv.2026.108862_bb0455","series-title":"Pipeline Overview","author":"Korro Bio","year":"2025"},{"key":"10.1016\/j.biotechadv.2026.108862_bb0460","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/nchembio.2007.16","article-title":"Splicing factor SF3b as a target of the antitumor natural product spliceostatin a","volume":"3","author":"Kotake","year":"2007","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0465","doi-asserted-by":"crossref","DOI":"10.1111\/liv.16123","article-title":"Global epidemiological impact of PNPLA3 I148M on liver disease","volume":"45","author":"Kozlitina","year":"2025","journal-title":"Liver Int."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0470","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41565-021-00898-0","article-title":"The current landscape of nucleic acid therapeutics","volume":"16","author":"Kulkarni","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0475","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1021\/acs.molpharmaceut.5b00364","article-title":"Exogenous DNA loading into extracellular vesicles via electroporation is size-dependent and enables limited gene delivery","volume":"12","author":"Lamichhane","year":"2015","journal-title":"Mol. Pharm."},{"issue":"1","key":"10.1016\/j.biotechadv.2026.108862_bb0480","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12985-025-02645-6","article-title":"Revolutionizing immunization: a comprehensive review of mRNA vaccine technology and applications","volume":"22","author":"Leong","year":"2025","journal-title":"Virol. J."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0485","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2023.1298441","article-title":"Using the structural diversity of RNA:protein interfaces to selectively target RNA with small molecules in cells: methods and perspectives","volume":"10","author":"Li","year":"2023","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0490","series-title":"Deepsilencer: A Novel Deep Learning Model for Predicting siRNA Knockdown Efficiency","author":"Liao","year":"2025"},{"key":"10.1016\/j.biotechadv.2026.108862_bb0495","first-page":"563","article-title":"Eteplirsen in Duchenne muscular dystrophy: drug development and future directions","volume":"77","author":"Lim","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.biotechadv.2026.108862_bb0500","series-title":"RNA Therapeutics Rewriting the Script of Medical Treatments","author":"Linzmeyer","year":"2023"},{"key":"10.1016\/j.biotechadv.2026.108862_bb0505","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jconrel.2022.05.043","article-title":"Circular RNA: An emerging frontier in RNA therapeutic targets, RNA therapeutics, and mRNA vaccines","volume":"348","author":"Liu","year":"2022","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.biotechadv.2026.108862_bb0510","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1586\/14760584.2015.965690","article-title":"Self-replicating alphavirus RNA vaccines","volume":"14","author":"Ljungberg","year":"2015","journal-title":"Expert Rev. Vaccines"},{"issue":"1","key":"10.1016\/j.biotechadv.2026.108862_bb0515","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12929-024-01080-z","article-title":"Current landscape of mRNA technologies and delivery systems for new modality therapeutics","volume":"31","author":"Lu","year":"2024","journal-title":"J. Biomed. Sci."},{"issue":"14","key":"10.1016\/j.biotechadv.2026.108862_bb0520","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.3390\/ijms21145130","article-title":"Self-amplifying RNA viruses as RNA vaccines","volume":"21","author":"Lundstrom","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.biotechadv.2026.108862_bb0525","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/17425247.2024.2445675","article-title":"Self-amplifying RNA virus vectors for drug delivery","volume":"22","author":"Lundstrom","year":"2025","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0530","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.110641","article-title":"Recent progress in gene therapy for familial hypercholesterolemia treatment","volume":"27","author":"Luo","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.biotechadv.2026.108862_bb0535","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s44307-025-00063-x","article-title":"Harnessing RNA base editing for diverse applications in RNA biology and RNA therapeutics","volume":"3","author":"Luo","year":"2025","journal-title":"Adv. Biotechnol. (Singap.)"},{"issue":"11","key":"10.1016\/j.biotechadv.2026.108862_bb0540","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.3390\/vaccines9111345","article-title":"The importance of RNA-based vaccines in the fight against COVID-19: an overview","volume":"9","author":"Machado","year":"2021","journal-title":"Vaccines"},{"issue":"11","key":"10.1016\/j.biotechadv.2026.108862_bb0545","doi-asserted-by":"crossref","first-page":"4964","DOI":"10.3390\/ijms26114964","article-title":"RNA through time: from the origin of life to therapeutic frontiers in transcriptomics and epitranscriptional medicine","volume":"26","author":"Mart\u00ednez-Campos","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biotechadv.2026.108862_bib912","first-page":"5","article-title":"RNA manufacturing for saRNA vaccines","volume":"4","author":"Maruggi","year":"2019","journal-title":"NPJ Vaccines"},{"issue":"1","key":"10.1016\/j.biotechadv.2026.108862_bb0550","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00424-023-02895-9","article-title":"Nobel prize for physiology or medicine in 2023: how to dupe the cellular innate immune system using modified RNA for therapeutic treatment","volume":"476","author":"Medenbach","year":"2024","journal-title":"Pflugers Arch. - Eur. J. Physiol."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0555","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/ana.23982","article-title":"Eteplirsen for the treatment of Duchenne muscular dystrophy","volume":"74","author":"Mendell","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0560","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.drudis.2012.03.002","article-title":"Cell-penetrating peptides: classes, origin, and current landscape","volume":"17","author":"Milletti","year":"2012","journal-title":"Drug Discov. Today"},{"issue":"4","key":"10.1016\/j.biotechadv.2026.108862_bb0565","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1080\/17460441.2024.2313455","article-title":"Recent applications of artificial intelligence in RNA-targeted small molecule drug discovery","volume":"19","author":"Morishita","year":"2024","journal-title":"Expert Opin. Drug Discov."},{"issue":"1","key":"10.1016\/j.biotechadv.2026.108862_bb0570","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102440","article-title":"Nucleic acid therapeutics: past, present, and future","volume":"36","author":"Naeem","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.biotechadv.2026.108862_bb0575","doi-asserted-by":"crossref","first-page":"16958","DOI":"10.1021\/ja505986a","article-title":"Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing","volume":"136","author":"Nair","year":"2014","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0580","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.tips.2025.01.002","article-title":"Poison exons: tuning RNA splicing for targeted gene regulation","volume":"46","author":"Neil","year":"2025","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0585","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1039\/D5PM00159E","article-title":"mRNA therapeutics beyond vaccines: dosing precision challenges and clinical translation framework","volume":"3","author":"Niazi","year":"2026","journal-title":"RSC Pharm."},{"issue":"1","key":"10.1016\/j.biotechadv.2026.108862_bb0590","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41392-023-01561-x","article-title":"Circular RNA vaccine in disease prevention and treatment","volume":"8","author":"Niu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0595","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1089\/nat.2018.0725","article-title":"Improving siRNA delivery in vivo through lipid conjugation","volume":"28","author":"Osborn","year":"2018","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0600","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1021\/acs.molpharmaceut.4c00744","article-title":"Computational methods for modeling lipid-mediated active pharmaceutical ingredient delivery","volume":"22","author":"Palonc\u00fdov\u00e1","year":"2025","journal-title":"Mol. Pharm."},{"issue":"21","key":"10.1016\/j.biotechadv.2026.108862_bb0605","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232112884","article-title":"Self-amplifying RNA approach for protein replacement therapy","volume":"23","author":"Papukashvili","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0610","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.coi.2020.01.008","article-title":"Recent advances in mRNA vaccine technology","volume":"65","author":"Pardi","year":"2020","journal-title":"Curr. Opin. Immunol."},{"issue":"11","key":"10.1016\/j.biotechadv.2026.108862_bb0615","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.3390\/pharmaceutics16111366","article-title":"The impact of COVID-19 on RNA therapeutics: a surge in lipid nanoparticles and alternative delivery systems","volume":"16","author":"Parvin","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biotechadv.2026.108862_bb0620","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/s41467-020-14527-2","article-title":"Naturally-occurring cholesterol analogues in lipid nanoparticles induce polymorphic shape and enhance intracellular delivery of mRNA","volume":"11","author":"Patel","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0625","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41540-023-00323-3","article-title":"Harnessing synthetic biology for advancing RNA therapeutics and vaccine design","volume":"9","author":"Pfeifer","year":"2023","journal-title":"NPJ Syst. Biol. Appl."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0630","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114197","article-title":"Microfluidic fabrication of lipid nanoparticles for the delivery of nucleic acids","volume":"184","author":"Prakash","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0635","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2022.942976","article-title":"History of development of the life-saving drug \u201cNusinersen\u201d in spinal muscular atrophy","volume":"16","author":"Qiu","year":"2022","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0640","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/s41587-019-0178-z","article-title":"Programmable RNA editing by recruiting endogenous ADAR using circular guide RNAs","volume":"37","author":"Qu","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0645","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jconrel.2013.08.005","article-title":"Chitosan-based siRNA delivery systems","volume":"172","author":"Ragelle","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biotechadv.2026.108862_bb0650","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3390\/pharmaceutics14020279","article-title":"Transferrin receptor-targeted nanocarriers: overcoming barriers to treat glioblastoma","volume":"14","author":"Ramalho","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biotechadv.2026.108862_bb0655","series-title":"Discovery of Risdiplam, A Selective Survival of Motor Neuron-2 (SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA)","author":"Ratni","year":"2018"},{"issue":"6","key":"10.1016\/j.biotechadv.2026.108862_bb0660","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1021\/acsmedchemlett.0c00659","article-title":"Risdiplam, the first approved small molecule splicing modifier drug as a blueprint for future transformative medicines","volume":"12","author":"Ratni","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0665","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.devcel.2024.12.038","article-title":"The regulatory landscape of 5\u2032 UTRs in translational control during zebrafish embryogenesis","volume":"60","author":"Reim\u00e3o-Pinto","year":"2025","journal-title":"Dev. Cell"},{"key":"10.1016\/j.biotechadv.2026.108862_bb0670","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0675","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abc9450","article-title":"CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy","volume":"6","author":"Rosenblum","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0680","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.ymthe.2018.03.010","article-title":"A novel amino lipid series for mRNA delivery: improved endosomal escape and sustained pharmacology and safety in non-human primates","volume":"26","author":"Sabnis","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0685","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101821","article-title":"Epigenetic modifications: key players in cancer heterogeneity and drug resistance","volume":"39","author":"Sadida","year":"2024","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0690","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrd4278","article-title":"mRNA-based therapeutics: developing a new class of drugs","volume":"13","author":"Sahin","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0695","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.biotechadv.2026.108862_bb0700","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.tig.2016.03.002","article-title":"Circular RNA stability advantages","volume":"32","author":"Salzman","year":"2016","journal-title":"Trends Genet."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0705","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.4161\/rna.22269","article-title":"Developing mRNA-vaccine technologies","volume":"9","author":"Schlake","year":"2012","journal-title":"RNA Biol."},{"issue":"5","key":"10.1016\/j.biotechadv.2026.108862_bb0710","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1093\/nar\/gkx060","article-title":"Characterizing the effect of GalNAc and phosphorothioate backbone on binding of antisense oligonucleotides to the asialoglycoprotein receptor","volume":"45","author":"Schmidt","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0715","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120586","article-title":"mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability","volume":"601","author":"Schoenmaker","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0720","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nm.4493","article-title":"H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers","volume":"24","author":"Seiler","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0725","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1177\/01926233241298572","article-title":"Session 4: mRNA and self-amplifying RNA (saRNA): opportunities for disease prevention and therapy","volume":"52","author":"Sellers","year":"2024","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0730","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.omtn.2020.11.008","article-title":"Circular RNA: an important player with multiple facets to regulate its parental gene expression","volume":"23","author":"Shao","year":"2021","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.biotechadv.2026.108862_bb0735","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.omtn.2021.05.022","article-title":"Recent research progress on circular RNAs: biogenesis, properties, functions, and therapeutic potential","volume":"25","author":"Sharma","year":"2021","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.biotechadv.2026.108862_bb0740","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/s41587-025-02708-7","article-title":"Individualized mRNA cancer vaccines make strides","volume":"43","author":"Sheridan","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0745","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/s41392-024-02002-z","article-title":"Progress and prospects of mRNA-based drugs in preclinical and clinical applications","volume":"9","author":"Shi","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0750","first-page":"19","article-title":"Investigating the frontiers of genetic regulation and unlocking the secrets of gene expression: the power of RNA-based therapeutics","volume":"1","author":"Siham","year":"2023","journal-title":"J. Clin. Genet. Hered."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0755","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.1015990","article-title":"Editorial: volume II: structural and functional characterization of circular RNAs","volume":"9","author":"Sinha","year":"2022","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0760","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107878","article-title":"In vivo repair of a protein underlying a neurological disorder by programmable RNA editing","volume":"32","author":"Sinnamon","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0765","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.chembiol.2024.05.006","article-title":"RNATACs: multispecific small molecules targeting RNA by induced proximity","volume":"31","author":"Song","year":"2024","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0770","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ccr.2009.10.013","article-title":"Tissue-penetrating delivery of compounds and nanoparticles into tumors","volume":"16","author":"Sugahara","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biotechadv.2026.108862_bb0775","doi-asserted-by":"crossref","first-page":"6023","DOI":"10.1093\/nar\/gkx135","article-title":"N1-methyl-pseudouridine in mRNA enhances translation through eIF2\u03b1-dependent and independent mechanisms by increasing ribosome density","volume":"45","author":"Svitkin","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0780","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101823","article-title":"Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-escalation study","volume":"56","author":"Szubert","year":"2023","journal-title":"eClinicalMedicine"},{"issue":"22","key":"10.1016\/j.biotechadv.2026.108862_bb0785","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252212284","article-title":"Recent advances and prospects in RNA drug development","volume":"25","author":"Tani","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"6558","key":"10.1016\/j.biotechadv.2026.108862_bb0790","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1126\/science.abe5650","article-title":"Geometric deep learning of RNA structure","volume":"373","author":"Townshend","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.biotechadv.2026.108862_bb0795","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.chembiol.2023.09.015","article-title":"Highly efficient cellular expression of circular mRNA enables prolonged protein expression","volume":"31","author":"Unti","year":"2024","journal-title":"Cell Chem. Biol."},{"issue":"4","key":"10.1016\/j.biotechadv.2026.108862_bb0800","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3390\/v17040566","article-title":"Self-amplifying RNA: advantages and challenges of a versatile platform for vaccine development","volume":"17","author":"Vallet","year":"2025","journal-title":"Viruses"},{"key":"10.1016\/j.biotechadv.2026.108862_bb0805","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/sj.bjc.6604801","article-title":"The spliceosome as target for anticancer treatment","volume":"100","author":"Van Alphen","year":"2009","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biotechadv.2026.108862_bb0810","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41541-022-00549-y","article-title":"A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability","volume":"7","author":"Voigt","year":"2022","journal-title":"npj Vaccines"},{"key":"10.1016\/j.biotechadv.2026.108862_bb0815","author":"Wave Life Sciences"},{"key":"10.1016\/j.biotechadv.2026.108862_bb0820","series-title":"WVE-006 for Alpha-1 Antitrypsin Deficiency ClinicalTrials.gov ID NCT06405633","author":"Wave Life Sciences","year":"2025"},{"issue":"9","key":"10.1016\/j.biotechadv.2026.108862_bb0825","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/mt.2015.138","article-title":"mRNA: fulfilling the promise of gene therapy","volume":"23","author":"Weissman","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0830","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107487","article-title":"Global and Chinese trends in oligonucleotide drug clinical development: a comparative analysis","volume":"210","author":"Wu","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0835","article-title":"Circular RNAs in gene therapy","volume":"8","author":"Xia","year":"2021","journal-title":"Front. Mol. Biosci."},{"issue":"1","key":"10.1016\/j.biotechadv.2026.108862_bib915","first-page":"76","article-title":"LNP delivery of circRNA","volume":"18","author":"Xu","year":"2023","journal-title":"Nat. Nanotechnol."},{"issue":"12","key":"10.1016\/j.biotechadv.2026.108862_bb0840","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.3390\/pharmaceutics14122682","article-title":"Recent advances in lipid nanoparticles for delivery of mRNA","volume":"14","author":"Yang","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biotechadv.2026.108862_bb0845","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1146\/annurev-cellbio-120420-125117","article-title":"Biogenesis and regulatory roles of circular RNAs","volume":"38","author":"Yang","year":"2022","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0850","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1038\/mt.2010.151","article-title":"Functional rescue of dystrophin-deficient mdx mice by a chimeric peptide\u2013PMO","volume":"18","author":"Yin","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0855","doi-asserted-by":"crossref","first-page":"604","DOI":"10.2174\/1389201019666180528084059","article-title":"Therapeutic potential of small activating RNAs (saRNAs) in human cancers","volume":"19","author":"Yoon","year":"2018","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0860","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1124\/pr.120.019554","article-title":"RNA drugs and RNA targets for small molecules: principles, progress, and challenges","volume":"72","author":"Yu","year":"2020","journal-title":"Pharmacol. Rev."},{"issue":"1","key":"10.1016\/j.biotechadv.2026.108862_bb0870","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12943-020-01224-3","article-title":"The role of N6-methyladenosine (m6A) modification in the regulation of circRNAs","volume":"19","author":"Zhang","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.biotechadv.2026.108862_bib914","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12929-023-00977-5","article-title":"mRNA-based vaccines and therapeutics: an in-depth survey of current and upcoming clinical applications","volume":"30","author":"Zang","year":"2023","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0875","article-title":"CircRNA-based cancer immunotherapy","volume":"21","author":"Zhang","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.biotechadv.2026.108862_bb0880","article-title":"Optimized lipid nanoparticles (LNPs) for organ-selective nucleic acids delivery in vivo","volume":"27","author":"Zhang","year":"2024","journal-title":"iScience"},{"issue":"3","key":"10.1016\/j.biotechadv.2026.108862_bb0885","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbaf263","article-title":"Artificial intelligence-driven circRNA vaccine development: multimodal collaborative optimization and a new paradigm for biomedical applications","volume":"26","author":"Zhao","year":"2025","journal-title":"Brief. Bioinform."},{"issue":"9","key":"10.1016\/j.biotechadv.2026.108862_bb0890","first-page":"1238","article-title":"Circularization strategies for RNA therapy","volume":"18","author":"Zhao","year":"2021","journal-title":"RNA Biol."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0895","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3390\/ph6010085","article-title":"Nanoparticle-based delivery of RNAi therapeutics: progress and challenges","volume":"6","author":"Zhou","year":"2013","journal-title":"Pharmaceuticals"},{"issue":"7","key":"10.1016\/j.biotechadv.2026.108862_bb0900","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/s41419-022-05075-2","article-title":"RNA-based therapeutics: an overview and prospectus","volume":"13","author":"Zhu","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0905","doi-asserted-by":"crossref","first-page":"0041","DOI":"10.34133\/bdr.0041","article-title":"CRISPR-Cas13: pioneering RNA editing for nucleic acid therapeutics","volume":"6","author":"Zhu","year":"2024","journal-title":"Biodes. Res."},{"key":"10.1016\/j.biotechadv.2026.108862_bb0910","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/wsbm.10","article-title":"Adenosine-to-inosine RNA editing","volume":"1","author":"Zinshteyn","year":"2009","journal-title":"Wiley Interdiscip. Rev. Syst. Biol. Med."}],"container-title":["Biotechnology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0734975026000686?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0734975026000686?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:51:07Z","timestamp":1784548267000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0734975026000686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":184,"alternative-id":["S0734975026000686"],"URL":"https:\/\/doi.org\/10.1016\/j.biotechadv.2026.108862","relation":{},"ISSN":["0734-9750"],"issn-type":[{"value":"0734-9750","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RNA therapeutics 2.0: Expanding the landscape from mRNA vaccines to splicing modulators and beyond","name":"articletitle","label":"Article Title"},{"value":"Biotechnology Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biotechadv.2026.108862","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108862"}}